EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
*.- Organization name : North Eastern Germany Society of Gynaecologic Oncology . *.- Organization study ID : NOGGO S16/COMPASS . *.- Sponsor : North Eastern Germany Society of Gynaecologic Oncology . ...